Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06971380 | Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis | recruiting | Phase 2 | 180 | Polina StepenskyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05294055 | Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma | recruiting | Phase 2 | 120 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06959732 | Zanubrutinib Combined With G-CVP in Previously Untreated FL | recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05635162 | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma(ZEBRA) | recruiting | Phase 2 | 50 | University College, LondonOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06140966 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03936153 | Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 170 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06918912 | Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure(LORELY) | recruiting | Phase 2 | 50 | Istituto Clinico HumanitasOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | recruiting | Phase 1 / Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 144 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04513639 | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | recruiting | Phase 2 / Phase 3 | 176 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06758375 | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients | recruiting | Phase 2 | 10 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06764017 | CHiR Therapy for Elderly DLBCL Intolerant to Chemo | recruiting | Phase 2 | 30 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06758037 | Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy(HiR+X) | recruiting | Phase 2 | 50 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06879379 | KPD Consolidation After ASCT in NDMM Patients | recruiting | Phase 2 / Phase 3 | 202 | Peking University People's HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06863584 | SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial | recruiting | Phase 2 | 41 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158386 | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158412 | All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma | recruiting | Phase 2 | 25 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06826118 | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | recruiting | Phase 2 | 15 | University of RochesterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma(FLAMMINGO) | recruiting | Phase 2 | 100 | BiocadINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06701357 | CR-CHOP+X in Previously Untreated DEL | recruiting | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06083207 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 116 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma(V-MIND) | recruiting | Phase 2 | 100 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06674096 | RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | recruiting | Phase 2 | 44 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05348213 | Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma(R-ICE+X) | recruiting | Phase 2 | 76 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06589089 | Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy | recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06647940 | Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06418477 | Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD | recruiting | Phase 2 | 20 | Peking University People's HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | recruiting | Phase 2 | 120 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 5 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06503263 | Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL | recruiting | Phase 2 | 240 | Navy General Hospital, BeijingOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2025source: clinicaltrials